Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC

Simple item page
dc.conference.dateDEC 08-11, 2021
dc.conference.titleESMO Immuno-Oncology Congres
dc.contributor.authorCho, B. C.
dc.contributor.authorRodriguez-Abreu, D.
dc.contributor.authorHussein, M.
dc.contributor.authorCobo, M.
dc.contributor.authorPatel, A.
dc.contributor.authorSecen, N.
dc.contributor.authorGerstner, G.
dc.contributor.authorKim, D-W.
dc.contributor.authorLee, Y-G.
dc.contributor.authorSu, W-C.
dc.contributor.authorHuang, E.
dc.contributor.authorPatil, N.
dc.contributor.authorHuang, M.
dc.contributor.authorZhang, Z.
dc.contributor.authorWen, X.
dc.contributor.authorMendus, D.
dc.contributor.authorHoang, T.
dc.contributor.authorMeng, R.
dc.contributor.authorJohnson, M. L.
dc.contributor.authoraffiliation[Cho, B. C.] Yonsei Univ Hlth Syst, Severance Hosp, Med Oncol, Seoul, South Korea
dc.contributor.authoraffiliation[Rodriguez-Abreu, D.] Hosp Univ Gran Canaria, Med Oncol, Las Palmas Gran Canaria, Spain
dc.contributor.authoraffiliation[Hussein, M.] Florida Canc Specialists, Med Oncol, Leesburg, VA USA
dc.contributor.authoraffiliation[Cobo, M.] Hosp Reg Univ Malaga, Med Oncol, Malaga, Spain
dc.contributor.authoraffiliation[Patel, A.] Florida Canc Specialists, Med Oncol, Sarasota, FL USA
dc.contributor.authoraffiliation[Secen, N.] Inst Lung Dis Vojvodina, Med Oncol, Sremska Kamenica, Serbia
dc.contributor.authoraffiliation[Gerstner, G.] Illinois Canc Care, Med Oncol, Peoria, IL USA
dc.contributor.authoraffiliation[Kim, D-W.] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
dc.contributor.authoraffiliation[Lee, Y-G.] Kangbuk Samsung Hosp, Med Oncol, Seoul, South Korea
dc.contributor.authoraffiliation[Su, W-C.] Natl Cheng Kung Univ Hosp, Med Oncol, Tainan, Taiwan
dc.contributor.authoraffiliation[Huang, E.] Roche Prod Ltd, Med Oncol, Welwyn Garden City, Herts, England
dc.contributor.authoraffiliation[Patil, N.] Genentech Inc, Biomarker Dev, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Huang, M.] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Wen, X.] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Mendus, D.] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Hoang, T.] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Meng, R.] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Zhang, Z.] Genentech Inc, Biostat, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Johnson, M. L.] Sarah Cannon Res Inst & Tennessee Onc PLLC, Med Oncol, Nashville, TN USA
dc.date.accessioned2025-01-07T12:22:35Z
dc.date.available2025-01-07T12:22:35Z
dc.date.issued2021-12-10
dc.identifier.doi10.1016/j.annonc.2021.10.217
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753421047736/pdf
dc.identifier.urihttps://hdl.handle.net/10668/24517
dc.identifier.wosID731051400120
dc.issue.number7
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.page.numberS1428-S1428
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleUpdated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía